List view / Grid view
non-small cell lung cancer (NSCLC)
Filter the results
The approval was based on a Phase III trial in which Libtayo reduced risk of death by 43 percent in non-small cell lung cancer patients with ≥50 percent PD-L1 expression in their tumours.
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
In a Phase II trial, sotorasib was shown to be effective against pre-treated non-small cell lung cancer (NSCLC).
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
The dose-finding trial will evaluate the safety and activity of UniCAR-T-PSMA in up to 16 patients with advanced relapsed/refractory, PSMA-positive solid tumours.
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
The US Food and Drug Administration (FDA) has granted Priority Review for capmatinib, a treatment for MET exon 14 skipping mutated non-small cell lung cancer.
As companies continue to collaborate and share their expertise to develop therapeutics targeting a wide range of diseases, European Pharmaceutical Review explores the aims of the most recent partnerships.
Sales of Merck’s drug Keytruda have grown beyond those of Bristol-Myers Squibb’s Opdivo, to become the global leading PD-1 inhibitor.